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ABSTRACT
Skin cancer, including melanoma, basal cell
carcinoma and cutaneous squamous cell carci-
noma, has one of the highest global incidences
of any form of cancer. In 2016 more than
16,000 people were diagnosed with melanoma
in the UK. Over the last decade the incidence of
melanoma has increased by 50% in the UK, and
about one in ten melanomas are diagnosed at a
late stage. Among the keratinocyte carcinomas
(previously known as non-melanoma skin can-
cers), basal cell carcinoma is the most common
cancer amongst Caucasian populations. The
main risk factor for all skin cancer is exposure to
ultraviolet radiation—more than 80% are
considered preventable. Primary care clinicians
have a vital role to play in detecting and
managing patients with skin lesions suspected
to be skin cancer, as timely diagnosis and
treatment can improve patient outcomes, par-
ticularly for melanoma. However, detecting
skin cancer can be challenging, as common
non-malignant skin lesions such as seborrhoeic
keratoses share features with less common skin
cancers. Given that more than 80% of skin
cancers are attributed to ultraviolet (UV) expo-
sure, primary care clinicians can also play an
important role in skin cancer prevention. This
article is one of a series discussing cancer pre-
vention and detection in primary care. Here we
focus on the most common types of skin cancer:
melanoma, squamous cell carcinoma and basal
cell carcinoma. We describe the main risk fac-
tors and prevention advice. We summarise key
guidance on the symptoms and signs of skin
cancers and their management, including their
initial assessment and referral. In addition, we
review emerging technologies and diagnostic
aids which may become available for use in
primary care in the near future, to aid the triage
of suspicious skin lesions.
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Key Summary Points
Skin cancer, including melanoma and
keratinocyte carcinomas (basal cell
carcinoma and cutaneous squamous cell
carcinoma), has one of the highest global
incidences of any form of cancer.
Incidence rates of these types of skin
cancer are increasing.
Primary care clinicians have a vital role to
play in detecting and managing patients
with skin lesions suspected to be cancer;
timely diagnosis and treatment can
improve patient outcomes, particularly
for melanoma. However, detecting skin
cancers can be challenging.
80% of skin cancers are considered
preventable, primarily through reduction
in exposure to the main risk factor, UV
radiation. Primary care clinicians can play
an important role in skin cancer
prevention through tailored advice about
the risks of UV exposure.
This article focusses on the most common
types of skin cancer: melanoma,
squamous cell carcinoma and basal cell
carcinoma. We describe the main risk
factors and prevention advice. We
summarise key guidance on the symptoms
and signs of skin cancers and their
management, including their initial
assessment and referral.
In addition, we review emerging
technologies and diagnostic aids, which at
present require more evidence for their
safety and efficacy, but may become
available for use in primary care in the
near future, to aid the triage of suspicious
skin lesions.
BACKGROUND
Skin cancer, including melanoma, basal cell
carcinoma (BCC) and cutaneous squamous cell
carcinoma (SCC), has one of the highest global
incidences of any form of cancer [1]. Melanoma
is the fifth most common cancer in the UK,
with around 16,000 patients diagnosed in 2016.
If melanoma is diagnosed at an early stage,
5-year survival can be up to 95%, making early
detection and treatment key to improving sur-
vival. However, melanoma is prone to metas-
tasise, making it responsible for up to 90% of
skin cancer deaths (2285 deaths in 2016 in the
UK) [2, 3]. Furthermore, among Caucasian
populations in the UK, the incidence of mela-
noma has quadrupled over the last 30 years, and
is expected to be among the cancers with the
fastest increasing incidence over the next
20 years, rising by a further 7% [4].
The ‘non-melanoma skin cancers’ (NMSC)
include SCC and BCC, although they arise from
keratinocyte cells and are increasingly known as
keratinocyte carcinomas (KCs) [5]. They are very
common. In the UK in 2015, more than 142,000
new cases were diagnosed, including about 80%
BCC and 20% SCC [6, 7]. Similar to melanoma,
the incidence of KCs has risen over recent dec-
ades, with an increase of 61% over the past
10 years alone [6].
In the UK, most patients with skin cancer
first present in primary care [8], where clinicians
then face the challenge of distinguishing a rare
possible skin cancer from common benign skin
lesions [9]. The National Cancer Diagnosis
Audit in England recently reported that the
median primary care interval (time from first
presentation to referral) for melanoma was
0 days, the joint lowest of the 21 cancers
reported [10]. Prolonged intervals of 60 and
90 days were experienced by 6% and 4.8% cases
respectively [10], suggesting that primary care
clinicians are generally accurate at recognising
suspicious skin lesions. However, among
patients referred with suspicious skin lesions via
an urgent suspected cancer ‘2-week-wait’
(2WW) system in England, only around 3% are
diagnosed with melanoma [11], suggesting that
improved primary care triage could reduce
burden on both patients and specialist care.
Although this article principally aims to support
primary care clinicians in the UK to recognise
and manage patients with possible skin cancer
in a timely way, it will also be of relevance to
clinicians in other healthcare systems. We
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focused on the National Institute for Health and
Care Excellence (NICE) guidelines, developed
for use in England and Wales, to direct the
discussion. We present melanoma and the ker-
atinocyte carcinomas separately, except when
their assessment and management can be con-
sidered together.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RISK FACTORS
Skin cancer incidence relates strongly to age,
with age-specific incidence rates rising sharply
from 50 years to peak in those over 75 years of
age. In contrast to most other cancers, 25% of
melanomas are diagnosed in those aged 50 and
under [12]. The main risk factor for all skin
cancers is preventable, namely exposure to
ultraviolet (UV) radiation, with more than 80%
of melanomas attributed to UV exposure
[13, 14]. This includes not only long-term
exposure but also short periods of intense sun
exposure or burning, especially in childhood or
with sunbed use. For SCCs, cumulative UV
exposure appears to be the main risk factor,
whereas intermittent UV exposure is the leading
risk factor for BCCs [15]. Other risk factors for
melanoma and KCs are listed in Fig. 1
[12, 16–21].
PREVENTION
Prevention of skin cancer focuses on patient
education about the risks and benefits of sun
exposure, and tailoring advice to the individual
patient risk [22, 23]. Figure 2 provides a sum-
mary of advice on avoiding sun exposure
[22–25]. A systematic review exploring complex
risk communication, undertaken to support
NICE guidelines on sunlight exposure [22],
found that only tailored messages (i.e. person-
alised to individual circumstances) had strong
evidence as a potentially effective strategy for
improving health behaviour outcomes. Relative
risk reduction (i.e. the relative decrease in the
risk of an adverse event in the group adhering to
preventative advice compared to the group not
following preventative advice) was thought to
be more persuasive in getting people to adopt
certain behaviours than other statistical pre-
sentations. There is evidence that interventions
based on the appearance-damaging effects of
UV exposure, and the positive effects of sun
protection, may be effective in altering beha-
viour [26]. Cancer Research UK have produced
numerous patient information resources as part
of their Sun Smart campaign [27], which can be
Fig. 1 Risk factors for melanoma and KCs
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used by clinicians to aid communication with
patients.
SCREENING
There is no evidence worldwide to support the
use of screening programs at a population level
[28, 29], although there is recent research
interest in using risk assessment models to
identify people at higher risk of melanoma, for
personalised approaches to surveillance [30–32].
Guidelines in the USA recommend screening for
patients at high risk of melanoma due to a
strong family or personal history of skin cancer
[33], and the Royal Australian College of Gen-
eral Practitioners’ guidance suggests a
6-monthly full-skin examination for patients at
high risk of melanoma and annually for those at
high risk of KC [25]. Interestingly, a recent sys-
tematic review assessing BCC screening against
the World Health Organisation screening crite-
ria [34] concluded that it may be beneficial for
lesions on the face.
DETECTING SKIN CANCER
IN PRIMARY CARE
Melanoma
Symptoms and Signs
The commonest subtype of melanoma is known
as superficial spreading melanoma: this classically
presents as a pigmented skin lesion (‘mole’) that
has changed in size, shape or colour [35] (Fig. 3).
It most commonly presents on the trunk in men
and on the legs in women [12]. Other mela-
noma subtypes include nodular melanoma
(5%), lentigo maligna (melanoma in situ,
4–15%), and acral lentiginous melanoma (5%)
[36, 37] and these may present in different
ways.
Nodular melanomas tend to occur on the head
and neck of older people: they grow quickly,
and are usually firm, symmetrical and evenly
pigmented papules or nodules, which may
ulcerate and bleed.
Lentigo maligna (also known as Hutchinson’s
freckle) develop as a slow-growing precursor
pigmented macule which may remain in situ for
many years. Once it becomes invasive it is
known as lentigo maligna melanoma and may
progress rapidly, often being poorly defined and
variably pigmented; they are much more com-
mon in people aged 60 and over.
Acral lentiginous melanomas occur exclusively
on the palms and soles and under nails, and are
thought to be unrelated to sun exposure.
Although uncommon among Caucasians, they
are commoner in people with pigmented or
Asian skin. They typically appear as a large
pigmented macule, but can mimic warts with a
verrucous, non-pigmented appearance [38–40].
An estimated 2–20% of melanomas are
amelanotic—these can appear as a non-pig-
mented mimic of any subtype, with nodular
melanomas the most likely to be amelanotic
[38]. They are more common in older age
groups over 70 years of age and in the head and
Fig. 2 Advice to give patients aiming to reduce sun exposure and risk of skin cancer [22–25]
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neck region, and tend to have worse outcomes
than pigmented melanomas [38].
Management
NICE guidance (2015) recommends using naked
eye examination and the weighted Glasgow
7-point checklist to assess suspicious skin
lesions (see Fig. 4; [24, 41, 42]). If a lesion scores
3 or more, then referral via an urgent suspected
cancer pathway is recommended [41]. There are
a number of other checklists available, such as
the ‘‘ABCDE’’ mnemonic, most commonly used
in North America, which refers to Asymmetry,
Border irregularity, Colour variation, Diameter
larger than 6 mm, Evolution/changing [43, 44].
NICE recommends that a suspected melanoma
Fig. 3 Clinical images of types of melanoma. a Superﬁcial
spreading melanoma. b Nodular melanoma. c Amelanotic
melanoma. d Lentigo maligna. e Acral lentiginous
melanoma. The images are reproduced with the kind
permission of the Primary Care Dermatology Society and
are available on their website: http://www.pcds.org.uk/
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should not be excised in primary care [45],
although a recent study suggests that no harm
came to patients undergoing primary care
excision in the rural Scottish setting [46]. To
avoid missing atypical melanomas, the NICE
clinical knowledge summary also recommends
referring the following lesions via an urgent
suspected cancer pathway: new nodules which
are pigmented or vascular in appearance; nail
change such as a new pigmented line or
pigmentation under the nail; or any skin lesion
that is persistent or slowly evolving and unre-
sponsive, with an uncertain diagnosis [24].
A routine referral for risk estimation, educa-
tion and possible surveillance should be con-
sidered for anyone who is potentially at high
risk for developing melanoma. This includes
those who have giant congenital pigmented
naevi (benign melanocytic naevi originating in
utero measuring greater than 20 cm in diameter
Fig. 4 a Weighted Glasgow 7-point checklist for assessing
suspicious pigmented skin lesions, as recommend by NICE
guidance (2015) [41, 42]. b Reassuring clinical features
that do not require referral to secondary care (unless there
are other concerning symptoms) as they suggest a benign
lesion [24]
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[47]), a family history of three or more mela-
noma cases, more than 100 normal moles, or
any atypical moles (particularly if multiple)
[24].
Squamous Cell Carcinoma (SCC)
Symptoms and Signs
SCCs tend to arise in areas that are frequently
exposed to the sun: face, scalp, ears, neck, and
upper limbs [48] (Fig. 5). Typically, they appear
either as an indurated (firm), nodular, crusted
lesion, or as an ulcer with no crusting [49, 50].
However, their appearance is variable and they
should be suspected in any lesion that is larger
than 1 cm, is non-healing, keratinized or crus-
ted, and has a documented expansion over the
past 8 weeks [51]. In situ SCC (Bowen’s disease)
typically appear as erythematous, scaly plaques
with clearly defined margins, but can some-
times be pigmented and flat with poorly defined
margins [19]. A variant of SCC is keratoacan-
thoma; these are domed, fast-growing, nodules
with a central hyperkeratotic region [52]. High-
risk SCCs include those on the lips, ears, non-
sun-exposed sites, in areas of previous injury,
those that are larger than 2 cm in diameter, are
in immunocompromised patients, or are a
recurrence of a previously treated lesion. These
have a higher probability of metastasis and
recurrence after treatment [45].
Management
As for melanoma, confirmation of an SCC relies
on excision and histopathological examination;
therefore all patients with a suspicious lesion
should be referred on an urgent suspected can-
cer pathway to secondary care [41].
bFig. 5 Clinical images of types of SCCs. a Well-differen-
tiated SCC. b SCC on scalp. c Poorly differentiated SCC.
d Keratoacanthoma. The images are reproduced with the
kind permission of the Primary Care Dermatology Society
and are available on their website: http://www.pcds.org.
uk/
Adv Ther
Fig. 6 Clinical images of types of BCC. a BCC. b Super-
ﬁcial BCC. c Morphoeic BCC. d Pigmented BCC.
e Basosquamous BCC. The images are reproduced with
the kind permission of the Primary Care Dermatology
Society and are available on their website: http://www.
pcds.org.uk/
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Basal Cell Carcinoma (BCC)
Symptoms and Signs
BCCs commonly arise in the head, neck, trunk
and limbs [20], but can be variable in their
clinical presentations (Fig. 6). There are several
histological subtypes [53] which may present
differently. Nodular and micro-nodular BCCs are
commonly found on the face and present as
pearly pink or white cystic papules or nodules
that have telangiectasia on their surface and
may be ulcerated. Superficial BCCs are usually on
the upper trunk and shoulders, and present as
erythematous, well-demarked, scaly plaques
with pearly white borders. They are often large
([20 mm), multiple and slow growing, and can
be confused with Bowen’s disease. Another
important mimic is amelanotic melanoma,
which can present as a red lesion and be con-
fused with a BCC [54]. Morphoeic BCCs (also
known as sclerosing or infiltrative) usually
occur on the face and present as skin-coloured,
waxy, scar-like lesions; they tend to recur and
can infiltrate cutaneous nerves. Pigmented BCCs
are brown, blue or greyish lesions that can
resemble melanomas. Baso squamous BCCs have
mixed BCC and SCC characteristics and can be
more aggressive than other forms of BCC
[53, 55, 56].
Management
The 2010 NICE guidance recommends that low-
risk BCCs (see Fig. 7) may be excised by primary
care clinicians with appropriate training
[53, 57]. This guidance may vary by local
agreement, depending on the clinicians’ role,
competencies and local policy. For all other
patients with a suspected BCC, routine referral
to specialist care is recommended, although, if
there is concern that a delay in referral will
make a ‘‘significant impact’’ because of factors
such as lesion site or size, then referral via an
urgent cancer pathway should be considered
[41].
Tools for Evaluating Suspicious Skin
Lesions in Primary Care
Dermoscopy
A dermatoscope is a handheld magnification
tool and light source which eliminates skin
Fig. 7 Features of low-risk BCCs [53]
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surface reflection, and can help assessment of
skin lesions with visualisation of deeper sub-
surface structures [58]. Dermoscopy performed
by trained specialists is both more sensitive and
specific in classifying skin lesions than clinical
examination with the naked eye alone [59, 60].
There have been two recent Cochrane reviews
of the evidence for dermoscopy to diagnose
keratinocyte carcinomas [61] and melanoma
[62]. Both found that most evidence was
derived from secondary care populations;
hence, there was insufficient evidence to sup-
port routine use of dermoscopy by primary care
clinicians. Our group’s recent systematic review
of dermoscopy use in primary care also found
the literature to be scanty; however, there was
some evidence that dermoscopy has the
potential to help primary care clinicians triage
suspicious lesions [63]. It also highlighted that
further evidence is needed on patient accept-
ability and minimum training requirements for
primary care clinicians to reach competence, as
well as the cost-effectiveness of implementing
dermoscopy in primary care.
Teledermatology
This term describes the use of information
technology to facilitate skin management, most
commonly by sharing digital images of lesions
with dermatology specialists. Teledermatology
referral systems are already well established in
some areas of the UK. A recent Cochrane review
assessing the diagnostic accuracy of telederma-
tology for detecting melanomas, BCCs and
SCCs in adults compared to face-to-face diag-
nosis by a specialist concluded that telederma-
tology is accurate for identifying the majority of
malignant lesions [64]. However, it also sug-
gested that further research is needed to fully
determine its diagnostic accuracy, feasibility
and cost-effectiveness as a triaging tool for
referring suspicious skin lesions from primary to
secondary care.
SIAscopy/MoleMate System
Spectrophotometric intracutaneous analysis
(SIAscopy) is a non-invasive scanning technol-
ogy, incorporated into the MoleMate system,
and evaluated in a randomised controlled trial
set in UK general practice. The MoleMate sys-
tem was not found to improve appropriateness
of referral, and its use led to a higher proportion
of lesions being referred [65]. However, there
was some evidence that a higher referral rate
from general practice may actually be cost-ef-
fective owing to improved outcomes associated
with earlier diagnosis of melanomas [66].
Artificial Intelligence (AI)-Supported Systems
The use of AI/machine learning to evaluate skin
lesions has received a huge amount of recent
attention in both the lay and medical press.
Experimental studies using images of lesions
from specialist clinics have shown that AI
algorithms can classify images of skin cancer
with an accuracy that matches or even exceeds
dermatologists [67, 68]. This suggests that AI
has the potential to assist primary care clini-
cians to triage suspicious skin lesions; research
is now needed on real-world primary care pop-
ulations to establish the accuracy and safety of
using these AI technologies in primary care.
Other Diagnostic Tools
Many other non-invasive tests and diagnostic
technologies have been developed to aid skin
cancer diagnosis, including high frequency
ultrasonography, optical coherence tomogra-
phy, reflectance confocal microscopy, and
computer-assisted diagnosis. They have been
evaluated in several recent Cochrane reviews,
all of which found a paucity of evidence for
their accuracy in either primary or specialist
care settings. Therefore, at present, there is
insufficient evidence to recommend their use
[64, 69–73].
CONCLUSIONS
Advice on limiting sun exposure remains an
important task for primary care clinicians,
especially among high-risk patient groups. Any
suspected melanomas or SCCs should be refer-
red via urgent cancer pathways to specialist care
for histological diagnosis and management.
Suspected BCCs should be referred routinely to
specialist care unless they are of concern
Adv Ther
because of their size or location, when they may
warrant urgent referral.
A number of diagnostic technologies are in
development, some of which may have a sig-
nificant impact on clinical practice. We may
therefore be on the verge of significant changes
in the detection of possible skin cancers in pri-
mary care. However, the evidence for the safe
and effective use of most of these technologies
by primary care clinicians is currently lacking.
There is weak evidence for use of dermoscopy
and teledermatology in primary care, but even
these approaches require further evaluation
before they can be recommended for wide-
spread implementation in primary care.
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